Wake Forest University Health Sciences

Open enrollment with an early-phase pipeline tilt

According to ClinicalTrials.gov-derived indexes, Wake Forest University Health Sciences sits in the top decile of US sponsors by registered trial count (#27 of 15,742 sponsors by registered trial count).

1,140 total trials 174 currently recruiting 724 completed early-phase tilt top decile by trial count

Wake Forest University Health Sciences: 1,140 sponsored US clinical trials, 174 recruiting.

Wake Forest University Health Sciences sponsors 1,140 registered US clinical trials on ClinicalTrials.gov, 174 of them currently recruiting, and 724 completed. 111 of these trials are in Phase 3-4 (later-stage) and 239 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Breast Cancer, with 9 trials.

Top-decile sponsor footprint

Wake Forest University Health Sciences ranks in the top decile of sponsors by registered trial count (#27 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.

Trial completion reliability score

F 44/100

724 of 885 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (81.8%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.

Open and recent trials

1,140 total, page 10 of 23

COMPLETED NA

Barbed Suture Versus Non-Barbed Suture for Posterior Colporrhaphy

NCT04658784

COMPLETED NA

Integrated Intervention for Caregivers--Open Trial

NCT03487575

COMPLETED NA

Incorporating Nutrition, Vests, Education, and Strength Training in Bone Health (INVEST in Bone Health)

NCT04076618

COMPLETED Early Phase 1

Fingolimod as a Treatment of Cerebral Edema After Intracerebral Hemorrhage

NCT04088630

COMPLETED NA

Study of KeraStat Cream for Radiation Dermatitis During Head and Neck Radiotherapy

NCT04173247

COMPLETED Phase 2

SNIFF Multi-Device Study 2

NCT04199767

COMPLETED NA

Stay In Treatment for Pediatric Weight Management

NCT04364282

COMPLETED NA

Implementation and Effectiveness of Engagement and Collaborative Management to Proactively Advance Sepsis Survivorship

NCT04495946

COMPLETED

Permanent Versus Delayed-Absorbable Monofilament Suture

NCT04506177

COMPLETED NA

VR System for Cross-modal Rehabilitation of Hemianopia

NCT04230486

COMPLETED NA

Project Relief: Developing Brain Stimulation as a Treatment for Chronic Pain

NCT04156802

COMPLETED NA

Awake-Prone Positioning Strategy for Hypoxic Patients With COVID-19

NCT04547283

COMPLETED NA

Theta Burst Stimulation as a Tool to Decrease Drinking in Treatment-seeking Alcohol Users

NCT04154111

COMPLETED Phase 4

Comparison of Bolus Dosing of Methohexital and Propofol in Elective Direct Current Cardioversion

NCT04187196

COMPLETED

Evaluation of a Personalized Care Management Program for High Hospital Utilizers

NCT04727567

TERMINATED Phase 2

Precision Medicine for Patients With Identified Actionable Mutations

NCT04111107

COMPLETED

COVID-19 Community Research Partnership

NCT04342884

COMPLETED Phase 1

Nivolumab Consolidation in Older (≥ 65) Patients With Primary CNS Lymphoma

NCT04022980

COMPLETED NA

Mindfulness During COVID-19

NCT04319445

COMPLETED

Computational Psychiatric Approach to Depression

NCT04189939

TERMINATED Phase 4

Interscalene Block With Liposomal Bupivacaine vs. Interscalene Block With Bupivacaine and Adjuvants

NCT03845894

COMPLETED NA

A Coordinated Parent/Child Dyad Weight Loss Intervention: Dyad Plus (Feasibility)

NCT03811743

COMPLETED

Rural Survivorship Navigation Program

NCT03880526

COMPLETED

TENS and Perioperative Fracture Patients

NCT04209673

COMPLETED NA

Nurse Initiated Acupressure for Pain Management

NCT04044716

COMPLETED NA

Ultrasound for the Detection of Oxaliplatin-Induced Peripheral Neuropathy

NCT03958747

COMPLETED NA

EMR Outcomes: Anxiety and Depression in Epilepsy

NCT03879525

TERMINATED NA

Exhaled Breath Analysis to Predict Risk of Symptomatic Pneumonitis

NCT04040244

COMPLETED

Evaluation of Extubation Criteria in Children With Upper Respiratory Infection (URI)

NCT04155892

COMPLETED NA

Development of Fluid Intake App for Management of Fluid Intake During Hemodialysis , Full Scale Trial

NCT04194164

COMPLETED Early Phase 1

Amnion Wound Covering for Enhanced Wound Healing

NCT03754218

COMPLETED NA

Molecular Transducers of Physical Activity Consortium (MoTrPAC) - Pediatric Protocol

NCT04151199

COMPLETED NA

Clinician Burnout and Social Determinants

NCT04070456

COMPLETED NA

Using Music During Lumbar Medial Branch Block Procedure

NCT04091607

COMPLETED Phase 4

Is 10 Injections of Bladder Botox Less Painful Than 20 Injections?

NCT04124939

COMPLETED NA

ICOLLAB FOR Children With Medical Complexity

NCT03978468

TERMINATED NA

Cryocompression Therapy for Peripheral Neuropathy in Patients With Multiple Myeloma

NCT03870451

COMPLETED NA

Effectiveness and Implementation of mPATH-CRC

NCT03843957

TERMINATED NA

Exercise Training and Metabolic Flexibility in Prediabetes

NCT04051229

COMPLETED Phase 4

Effects of Intramuscular (IM) Oxytocin on Pupil Diameter and Heart Rate Variability (HRV)

NCT04105998

TERMINATED

Bioenergetic Profiling and Cognition in GBM Patients

NCT03939858

COMPLETED NA

A Virtual Navigation Intervention to Reduce Behavioral Health Admissions From Rural Emergency Departments

NCT04148521

TERMINATED NA

Metabolic and Microbial Profiling of Lung Cancer

NCT03998189

COMPLETED Phase 4

Angiotensin II in General Anesthesia

NCT03733145

COMPLETED Phase 4

Opioid Free Management After Ureteroscopy

NCT03872843

COMPLETED NA

High-Resolution Anoscopy Perceived Discomfort Study

NCT04083053

TERMINATED

Emission Patterns of Respiratory Syncytial Virus

NCT03909867

COMPLETED NA

Pragmatic Investigation of Volume Targeted Ventilation-1

NCT03909854

COMPLETED

DHS MIND Metabolomics

NCT03975309

COMPLETED NA

Molecular Transducers of Physical Activity Consortium

NCT03960827

← Previous Page 10 of 23 Next →

Phase Distribution

PhaseTrial count
Phase 1 96
Phase 2 143
Phase 3 31
Phase 4 80

What is open in the Wake Forest University Health Sciences pipeline

174 recruiting of 1,140 indexed (15% open); 724 completed (64%).

Phase mix: 111 late (III/IV) vs 239 early (I/II) (early-phase heavy).

Top condition: Breast Cancer (9 trials), 9 others listed.

How open-pipeline share is computed

Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.

Wake Forest University Health Sciences: open-pipeline peers nationwide

Peers matched on 1,140 registered trials and 15% open enrollment, not the therapeutic-area sidebar.

Wake Forest University Health Sciences sits at or above the median trial volume and below the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 05001,0001,500 8%10%12%14%16%18%20% Total trials Recruiting share Wake Forest University Health SciencesUniversity of Alabama at BirminghamNYU Langone HealthUniversity of North Carolina, Chapel HillUniversity of FloridaBaylor UniversityCornell UniversityArrowhead Regional Medical CenterAurinia Pharmaceuticals
Wake Forest University Health Sciences sits at or above the median trial volume and below the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

Wake Forest University Health Sciences sits at or above the median trial volume and below the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 1,140 trials (± recruiting share)

Sponsors near 15% open enrollment (± trial volume)

What to do with this Wake Forest University Health Sciences page

1,140 registered trials is a research-attention snapshot, not an endorsement of Wake Forest University Health Sciences or any single study.

  • 174 of Wake Forest University Health Sciences's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
  • Breast Cancer is the condition Wake Forest University Health Sciences studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Breast Cancer trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. Wake Forest University Health Sciences pipeline card: 1,140 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.